Biobank study of blood and tumour samples from patients with aggressive cancers
Collects blood and tumour samples from people with hard-to-treat cancers to study immune markers.
Plain-language title generated from the registry record
Registry title: Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Key facts
- Where
- Saint Petersburg, RussiaSee the site
Where in Russia
- N.N. Petrov NMRC of Oncology, Oncoimmunology dep.Saint Petersburg, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- N.N. Petrov National Medical Research Center of Oncology
- Trial code
- NCT05539677
- Record updated
- 6 May 2024
- Original description
The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategiesRead full original descriptionShow less
Analysis of the Immunogenetic Profile of Patients With Aggressive Course of Malignant Neoplastic Process Resistant to the Standard Treatment Approaches: a Translational Study
The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies
Inclusion: Signed inform consent; Histolgically verified solid tumour; Receiving systemic therapy for neoplasm; Has archival tumour tissue; Provide biosamples with living tumour tissue or blood samples for immunologic assessment.
Exclusion: Concurrent Lymphoprolipherative disorder; Patients receiving immunosupressive therapy for concurrent illness; Incomplete informaton on previous cancer history or medical history; Patients after stem cell or bone marrow thansplantation; Patients with known primary immunodeficiency; Pregnant patients.